Cytokine Profiles of Patients with Psoriasis Vulgaris who Experienced Acute Respiratory Infection with COVID-19

Yanina  Kutasevych; Hanna Kondakova; Svitlana  Dzhoraieva; Oksana  Sokol; Zoya  Shevchenko

doi:10.3889/oamjms.2024.11808

Authors

Yanina Kutasevych State Establishment “Institute of Dermatology and Venereology of National Academy of Sciences of Ukraine,” Kharkiv, Ukraine
Hanna Kondakova State Establishment “Institute of Dermatology and Venereology of National Academy of Sciences of Ukraine,” Kharkiv, Ukraine https://orcid.org/0000-0002-7739-1922
Svitlana Dzhoraieva State Establishment “Institute of Dermatology and Venereology of National Academy of Sciences of Ukraine,” Kharkiv, Ukraine
Oksana Sokol State Establishment “Institute of Dermatology and Venereology of National Academy of Sciences of Ukraine,” Kharkiv, Ukraine
Zoya Shevchenko State Establishment “Institute of Dermatology and Venereology of National Academy of Sciences of Ukraine,” Kharkiv, Ukraine

DOI:

https://doi.org/10.3889/oamjms.2024.11808

Keywords:

psoriasis, cytokines, COVID-19, treatment

Abstract

BACKGROUND: COVID-19, developing hyper-inflammatory reactions, can be a trigger factor for the manifestation or exacerbation of psoriasis in people who have undergone this infection. According to the scientific literature, patients with psoriasis are more likely to be infected with a coronavirus infection than the healthy population. However, they tolerate it in a milder form. At the same time, there have been reported exacerbation cases of the psoriatic process during the active phase of the disease and after experiencing COVID-19.

AIM: The purpose of the study is to analyze the profiles of cytokines interleukin (IL)-17, IL-10, IL-8. IL-6, IL-4, and IL-1b in patients with psoriasis vulgaris and patients with psoriasis who contracted COVID-19.

METHODS: We examined two groups of patients: The first group – 46 patients with psoriasis vulgaris in the period of exacerbation of the disease; the second group – 15 patients with exacerbation of psoriasis who contracted a mild or moderately severe coronavirus infection. The control group consisted of 15 conditionally healthy donors. The levels of cytokines IL-1b, IL-6, IL-8, IL-17a, IL-4, and IL-10 in the blood of patients and practically healthy individuals were determined by the enzyme immunoenzymatic method, using the “Human ELISE Kit” reagent sets (Fine Biotech., China), according to the manufacturer’s instructions. The difference between the study groups was assessed using the Mann–Whitney U-test. The results were considered significant at p < 0.01. All calculations were carried out using Microsoft Excel (Office 365).

RESULTS: Psoriasis patients who have contracted COVID-19 had higher levels of IL-1b, IL-6, and IL-8 in their blood than patients with psoriasis vulgaris.

CONCLUSION: Increased levels of IL-1β, IL-6, and IL-8 in the blood of patients with psoriasis may be a trigger factor for acute psoriasis in patients who have suffered from COVID-19.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Menter A, Cordoro KM, Davis DM, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American academy of dermatology- national psoriasis foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161-201. Erratum in: J Am Acad Dermatol. 2020;82(3):574. https://doi.org/10.1016/j.jaad.2019.08.049 PMid:31703821 DOI: https://doi.org/10.1016/j.jaad.2019.08.049

Turchin I, Bourcier M. The role of interleukins in the pathogenesis of dermatological immune-mediated diseases. Adv Ther. 2022;39(10):4474-508. https://doi.org/10.1007/s12325-022-02241-y PMid:35997892 DOI: https://doi.org/10.1007/s12325-022-02241-y

Griffiths CE, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis. Lancet. 2021;397(10281):1301-15. https://doi.org/10.1016/S0140-6736(20)32549-6 PMid:33812489 DOI: https://doi.org/10.1016/S0140-6736(20)32549-6

Shah P, Zampella JG. Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic. J Am Acad Dermatol. 2020;82(6):e203-4. https://doi.org/10.1016/j.jaad.2020.03.056 PMid:32244021 DOI: https://doi.org/10.1016/j.jaad.2020.03.056

Su CM, Wang L, Yoo D. Activation of NF-B and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2. Sci Rep. 2021;11(1):13464. https://doi.org/10.1038/s41598-021-92941-2 PMid:34188167 DOI: https://doi.org/10.1038/s41598-021-92941-2

Ozaras R, Berk A, Ucar DH, Duman H, Kaya F, Mutlu H. Covid-19 and exacerbation of psoriasis. Dermatol Ther. 2020;33(4):e13632. https://doi.org/10.1111/dth.13632 PMid:32436303 DOI: https://doi.org/10.1111/dth.13632

Kašnar AM, Jurić K, Franić A, Čeović R. Current knowledge on psoriasis during the covid-19 pandemic. Acta Dermatovenerol Croat. 2022;30(2):99-105. PMid:36254542

Bardazzi F, Loi C, Sacchelli L, Di Altobrando A. Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. J Dermatolog Treat. 2020;31(4):320-1. https://doi.org/10.1080/09546634.2020.1749545 PMid:32248724. DOI: https://doi.org/10.1080/09546634.2020.1749545

Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. Biologic therapy for psoriasis during the COVID-19 outbreak: The choice is to weigh risks and benefits. Dermatol Ther. 2020;33(4):e13490. https://doi.org/10.1111/dth.13490 PMid:32358864 DOI: https://doi.org/10.1111/dth.13490

Di Lernia V, Goldust M, FeLiciani C. Covid-19 infection in psoriasis patients treated with cyclosporin. Dermatol Ther. 2020;33(4):e13739. https://doi.org/10.1111/dth.13739 PMid:32478942 DOI: https://doi.org/10.1111/dth.13739

Megna M, Ruggiero A, Marasca C, Fabbrocini G. Biologics for psoriasis patients in the COVID-19 era: More evidence, Less fears. J Dermatolog Treat. 2020;31(4):328-9. https://doi.org/10.1080/09546634.2020.1757605 PMid:32301363 DOI: https://doi.org/10.1080/09546634.2020.1757605

Gisondi P, Facheris P, Dapavo P, Piaserico S, Conti A, Naldi L, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: The Northern Italy experience. Br J Dermatol. 2020;183(2):373-4.

https://doi.org/10.1111/bjd.19158 PMid: 32343839 DOI: https://doi.org/10.1111/bjd.19158

Carugno A, Gambini DM, Raponi F, Vezzoli P, Locatehi AG, Di Mercurio M, et al. COVID-19 and biologics for psoriasis: A high- epidemic area experience-Bergamo, Lombardy, Italy. J Am Acad Dermatol. 2020;83(1):292-4. https://doi.org/10.1016/jaad.2020.04.165 PMid: 32387660 DOI: https://doi.org/10.1016/j.jaad.2020.04.165

Kopcha VS. Osoblyvosti imunozalezhnykh proiaviv pry COVID-19 [Features of immune-dependent manifestations with COVID-19]. Infect Dis. 2021;2(104):4-16. https://doi.org/10.11603/1681-2727.2021.2.12159 DOI: https://doi.org/10.11603/1681-2727.2021.2.12159

Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nat Med. 2000;6(5):583-8. Erratum in: Nat Med. 2010;16(11):1341. https://doi.org/10.1038/75068 PMid:10802717 DOI: https://doi.org/10.1038/nm1110-1341

Christophers E, Metzler G, Röcken M. Bimodal immune activation in psoriasis. Br J Dermatol. 2014;170(1):59-65. https://doi.org/10.1111/bjd.12631 PMid:24117368 DOI: https://doi.org/10.1111/bjd.12631

Patrick MT, Zhang H, Wasikowski R, Prens EP, Weidinger S, Gudjonsson JE, et al. Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. J Allergy Clin Immunol. 2021;147(3):857-69.e7. https://doi.org/10.1016/j.jaci.2021.01.006 PMid:33485957 DOI: https://doi.org/10.1016/j.jaci.2021.01.006